Breaking News

BioNxt Completes Pilot Study for Contract Development Customer

Successfully developed the ODF narcotics product and managed the comparative bioavailability study.

BioNxt has successfully completed a human pilot study for a leading European-based generic drug company. BioNxt successfully developed the oral dissolvable (ODF) narcotics product and managed the comparative bioavailability study. “BioNxt is actively building a development pipeline of in-house and contract drug formulation programs,” said Hugh Rogers, CEO of BioNxt. “We are very pleased with the recent success of our contract development products. This presents an attractive...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters